{"organizations": [], "uuid": "ff0dcbd031479f77d91ac80f4f2d8ae53d9c8a03", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180518.html", "section_title": "Archive News &amp; Video for Friday, 18 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/us-health-ebola-zmapp/who-expects-to-get-approval-to-use-zmapp-ebola-drug-in-congo-idUSKCN1IJ20K", "country": "US", "domain_rank": 408, "title": "WHO expects to get approval to use ZMapp Ebola drug in Congo", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.007, "site_type": "news", "published": "2018-05-18T23:16:00.000+03:00", "replies_count": 0, "uuid": "ff0dcbd031479f77d91ac80f4f2d8ae53d9c8a03"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-health-ebola-zmapp/who-expects-to-get-approval-to-use-zmapp-ebola-drug-in-congo-idUSKCN1IJ20K", "ord_in_thread": 0, "title": "WHO expects to get approval to use ZMapp Ebola drug in Congo", "locations": [], "entities": {"persons": [{"name": "catherine evans", "sentiment": "none"}, {"name": "peter salama", "sentiment": "none"}, {"name": "kate kelland", "sentiment": "none"}, {"name": "tom miles", "sentiment": "none"}], "locations": [{"name": "democratic republic of congo", "sentiment": "none"}, {"name": "congo geneva", "sentiment": "none"}, {"name": "geneva", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "world health organization", "sentiment": "negative"}, {"name": "who", "sentiment": "negative"}, {"name": "mapp biopharmaceutical", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "GENEVA (Reuters) - The World Health Organization is discussing with Democratic Republic of Congo whether the government will give approval for the use of Mapp Biopharmaceutical’s experimental ZMapp treatment for Ebola, a senior WHO official said on Friday.\n“We believe it’s likely in the coming days,” WHO’s Deputy Director-General of Emergency Preparedness and Response Peter Salama told a news conference in Geneva.\nReporting by Tom Miles and Kate Kelland; Editing by Catherine Evans\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-18T23:16:00.000+03:00", "crawled": "2018-05-19T15:13:02.006+03:00", "highlightTitle": ""}